The virus that causes COVID-19 today is not the same as the one that first sickened people way back in December 2019. Many of the variants circulating now are partially resistant to some of the antibody-based therapeutics that were developed based on the original virus. As the pandemic continues, more […]
The levels of IgG antibodies against SARS-CoV-2 Spike protein remain stable, or even increase, seven months after infection, according to a follow-up study in a cohort of healthcare workers coordinated by the Barcelona Institute for Global Health (ISGlobal), an institution supported by “la Caixa” Foundation, in collaboration with the Hospital […]
The US Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc’s COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people. The company said the authorization enables the therapy to be used in people exposed to an infected individual, or […]
America’s COVID-19 doctor, Anthony Fauci, MD, says he won’t bother taking an antibody test to find out whether he needs a coronavirus vaccine booster shot. “If I went to LabCorp or one of those places and said, ‘I would like to get the level of anti-spike antibodies,’ I could tell what my level is, if […]
Betacoronaviruses (betaCoVs) caused the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks, and the SARS-CoV-2 pandemic1–4. Vaccines that elicit protective immunity against SARS-CoV-2 and betaCoVs circulating in animals have the potential to prevent future betaCoV pandemics. Here, we show that macaque immunization with a multimeric SARS-CoV-2 […]
Highlights Broad variation in neutralizing antibodies in SARS-CoV-2-convalescent individuals. ∼3% individuals showed a potent antibody response with SARS-CoV-1 cross-reactivity. Older age, symptomatic and severe disease predict higher SARS-CoV-2 neutralization. Serum and IgG neutralization half-lives were 14.7 and 31.4 weeks respectively. Summary Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the […]
Summary Background Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. Methods A large, multicentre, prospective cohort study was done, […]
The efficacy of two injections of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike messenger RNA (mRNA) vaccines (BNT162b2 [Pfizer] and mRNA-1273 [Moderna])1 in preventing symptomatic SARS-CoV-2 infection in persons without previous coronavirus disease 2019 (Covid-19) has been shown to be high. We wondered what the response would be to the […]
Monoclonal antibody treatment: GlaxoSmithKline and Vir Biotechnology are seeking emergency use authorization for their investigational monoclonal antibody treatment for early COVID-19. In an interim analysis of an efficacy trial of nearly 600 adults with COVID-19 who were at high risk for hospitalization, VIR-7831 was associated with an 85% lower risk […]
